Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Pretreatment metabolic tumor volumes to predict the short-term outcome of unresectable locally advanced squamous cell carcinoma of the esophagus treated with definitive chemoradiotherapy.

Chen SW, Hsieh TC, Ding HJ, Yen KY, Lin CY, Liang JA, Kao CH.

Nucl Med Commun. 2014 Mar;35(3):291-7. doi: 10.1097/MNM.0000000000000046.

PMID:
24276528
2.
3.

18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma.

Lim R, Eaton A, Lee NY, Setton J, Ohri N, Rao S, Wong R, Fury M, Schöder H.

J Nucl Med. 2012 Oct;53(10):1506-13. doi: 10.2967/jnumed.111.101402. Epub 2012 Aug 14.

4.

Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma.

Hyun SH, Choi JY, Shim YM, Kim K, Lee SJ, Cho YS, Lee JY, Lee KH, Kim BT.

Ann Surg Oncol. 2010 Jan;17(1):115-22. doi: 10.1245/s10434-009-0719-7. Epub 2009 Oct 14.

PMID:
19826877
5.

Role of surgical resection in complete responders on FDG-PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.

Jeong Y, Kim JH, Kim SB, Yoon DH, Park SI, Kim YH, Kim HR, Jung HY, Lee GH, Ryu JS.

J Surg Oncol. 2014 Apr;109(5):472-7. doi: 10.1002/jso.23514. Epub 2013 Dec 2.

PMID:
24301552
6.

Pretreatment metabolic tumour volume is predictive of disease-free survival and overall survival in patients with oesophageal squamous cell carcinoma.

Lemarignier C, Di Fiore F, Marre C, Hapdey S, Modzelewski R, Gouel P, Michel P, Dubray B, Vera P.

Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2008-16. doi: 10.1007/s00259-014-2839-y. Epub 2014 Jul 19.

PMID:
25037871
7.
8.

Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.

Higuchi I, Yasuda T, Yano M, Doki Y, Miyata H, Tatsumi M, Fukunaga H, Takiguchi S, Fujiwara Y, Hatazawa J, Monden M.

J Thorac Cardiovasc Surg. 2008 Jul;136(1):205-12, 212.e1-3. doi: 10.1016/j.jtcvs.2008.02.016. Epub 2008 May 27.

9.

Application of sequential (18)F-FDG PET/CT scans for concurrent chemoradiotherapy of non-surgical squamous cell esophageal carcinoma.

Li Y, Lin Q, Wang L, Sun L, Dai M, Luo Z, Zheng H, Zhao L, Wu H.

J BUON. 2014 Apr-Jun;19(2):517-23.

PMID:
24965415
10.

Clinical significance of pretreatment metabolic tumor volume and total lesion glycolysis in hypopharyngeal squamous cell carcinomas.

Roh JL, Kim JS, Kang BC, Cho KJ, Lee SW, Kim SB, Choi SH, Nam SY, Kim SY.

J Surg Oncol. 2014 Dec;110(7):869-75. doi: 10.1002/jso.23729. Epub 2014 Aug 2.

PMID:
25088392
11.

Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer.

Jayachandran P, Pai RK, Quon A, Graves E, Krakow TE, La T, Loo BW Jr, Koong AC, Chang DT.

Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):471-7. doi: 10.1016/j.ijrobp.2011.12.029. Epub 2012 Feb 28.

PMID:
22381904
12.

Prognostic value of pretreatment 18F-fluorodeoxyglucose uptake in patients with cervical cancer treated with definitive chemoradiotherapy.

Onal C, Reyhan M, Parlak C, Guler OC, Oymak E.

Int J Gynecol Cancer. 2013 Jul;23(6):1104-10. doi: 10.1097/IGC.0b013e3182989483.

PMID:
23792605
13.

Postradiation metabolic tumor volume predicts outcome in head-and-neck cancer.

Murphy JD, La TH, Chu K, Quon A, Fischbein NJ, Maxim PG, Graves EE, Loo BW Jr, Le QT.

Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):514-21. doi: 10.1016/j.ijrobp.2010.01.057. Epub 2010 Jun 18.

14.

Pretreatment (18)F-FDG PET/CT in whole-body total lesion glycolysis to predict survival in patients with pharyngeal cancer treated with definitive radiotherapy.

Chen SW, Hsieh TC, Yen KY, Liang JA, Kao CH.

Clin Nucl Med. 2014 May;39(5):e296-300. doi: 10.1097/RLU.0000000000000243.

PMID:
24217547
15.

Use of pretreatment metabolic tumour volumes to predict the outcome of pharyngeal cancer treated by definitive radiotherapy.

Kao CH, Lin SC, Hsieh TC, Yen KY, Yang SN, Wang YC, Liang JA, Hua CH, Chen SW.

Eur J Nucl Med Mol Imaging. 2012 Aug;39(8):1297-305. doi: 10.1007/s00259-012-2127-7. Epub 2012 Apr 25.

PMID:
22532254
16.

The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma. A prospective, multicentre study (RTEP3).

Palie O, Michel P, Ménard JF, Rousseau C, Rio E, Bridji B, Benyoucef A, Meyer ME, Jalali K, Bardet S, M'vondo CM, Olivier P, Faure G, Itti E, Diana C, Houzard C, Mornex F, Di Fiore F, Vera P.

Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1345-55. doi: 10.1007/s00259-013-2450-7. Epub 2013 May 29.

PMID:
23715903
17.

The value of ¹⁸F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy.

Myslivecek M, Neoral C, Vrba R, Vomackova K, Cincibuch J, Formanek R, Koranda P, Zapletalova J.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012 Jun;156(2):171-9. doi: 10.5507/bp.2011.048.

18.

Interim FDG PET/CT for predicting the outcome in patients with head and neck cancer.

Chen SW, Hsieh TC, Yen KY, Yang SN, Wang YC, Chien CR, Liang JA, Kao CH.

Laryngoscope. 2014 Dec;124(12):2732-8. doi: 10.1002/lary.24826. Epub 2014 Jul 10.

PMID:
25042474
19.

Predictive and prognostic value of metabolic tumor volume (MTV) in patients with laryngeal carcinoma treated by radiotherapy (RT) / concurrent chemoradiotherapy (CCRT).

Yabuki K, Shiono O, Komatsu M, Sano D, Nishimura G, Takahashi M, Taguchi T, Inoue T, Oridate N.

PLoS One. 2015 Feb 18;10(2):e0117924. doi: 10.1371/journal.pone.0117924. eCollection 2015.

20.

Can adaptive threshold-based metabolic tumor volume (MTV) and lean body mass corrected standard uptake value (SUL) predict prognosis in head and neck cancer patients treated with definitive radiotherapy/chemoradiotherapy?

Akagunduz OO, Savas R, Yalman D, Kocacelebi K, Esassolak M.

Nucl Med Biol. 2015 Nov;42(11):899-904. doi: 10.1016/j.nucmedbio.2015.06.007. Epub 2015 Jun 22.

PMID:
26275933
Items per page

Supplemental Content

Write to the Help Desk